SANOFI-ADR (SNY) Stock Fundamental Analysis
USA - NASDAQ:SNY - US80105N1054 - ADR
48.89 USD
-0.66 (-1.33%)
48.89 USD
0 (0%)
SNY gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While SNY belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. SNY is valued quite cheap, while showing a decent growth score. This is a good combination! SNY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
SNY had positive earnings in the past year.
In the past year SNY had a positive cash flow from operations.
In the past 5 years SNY has always been profitable.
Each year in the past 5 years SNY had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 11.05%, SNY belongs to the top of the industry, outperforming 92.71% of the companies in the same industry.
SNY has a better Return On Equity (19.73%) than 90.63% of its industry peers.
The Return On Invested Capital of SNY (13.84%) is better than 92.19% of its industry peers.
The Average Return On Invested Capital over the past 3 years for SNY is significantly below the industry average of 13.48%.
The last Return On Invested Capital (13.84%) for SNY is above the 3 year average (7.31%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROIC | 13.84% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
1.3 Margins
SNY has a Profit Margin of 20.35%. This is amongst the best in the industry. SNY outperforms 91.67% of its industry peers.
In the last couple of years the Profit Margin of SNY has grown nicely.
The Operating Margin of SNY (23.59%) is better than 89.58% of its industry peers.
SNY's Operating Margin has improved in the last couple of years.
SNY's Gross Margin of 71.70% is fine compared to the rest of the industry. SNY outperforms 77.60% of its industry peers.
SNY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% |
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
2. Health
2.1 Basic Checks
SNY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
SNY has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, SNY has about the same amount of shares outstanding.
Compared to 1 year ago, SNY has an improved debt to assets ratio.
2.2 Solvency
The Debt to FCF ratio of SNY is 2.21, which is a good value as it means it would take SNY, 2.21 years of fcf income to pay off all of its debts.
SNY's Debt to FCF ratio of 2.21 is amongst the best of the industry. SNY outperforms 92.19% of its industry peers.
A Debt/Equity ratio of 0.21 indicates that SNY is not too dependend on debt financing.
SNY has a Debt to Equity ratio (0.21) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Altman-Z | N/A |
ROIC/WACC1.86
WACC7.46%
2.3 Liquidity
SNY has a Current Ratio of 1.27. This is a normal value and indicates that SNY is financially healthy and should not expect problems in meeting its short term obligations.
SNY's Current ratio of 1.27 is on the low side compared to the rest of the industry. SNY is outperformed by 77.60% of its industry peers.
A Quick Ratio of 0.94 indicates that SNY may have some problems paying its short term obligations.
With a Quick ratio value of 0.94, SNY is not doing good in the industry: 77.60% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 |
3. Growth
3.1 Past
The earnings per share for SNY have decreased by -5.35% in the last year.
SNY shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.10% yearly.
SNY shows a small growth in Revenue. In the last year, the Revenue has grown by 2.56%.
The Revenue has been growing slightly by 3.31% on average over the past years.
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%
3.2 Future
SNY is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.06% yearly.
Based on estimates for the next years, SNY will show a small growth in Revenue. The Revenue will grow by 4.52% on average per year.
EPS Next Y3.07%
EPS Next 2Y5.75%
EPS Next 3Y6.01%
EPS Next 5Y7.06%
Revenue Next Year0.53%
Revenue Next 2Y3.48%
Revenue Next 3Y4.4%
Revenue Next 5Y4.52%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 11.11, the valuation of SNY can be described as very reasonable.
SNY's Price/Earnings ratio is rather cheap when compared to the industry. SNY is cheaper than 88.54% of the companies in the same industry.
When comparing the Price/Earnings ratio of SNY to the average of the S&P500 Index (25.07), we can say SNY is valued rather cheaply.
A Price/Forward Earnings ratio of 9.83 indicates a reasonable valuation of SNY.
86.46% of the companies in the same industry are more expensive than SNY, based on the Price/Forward Earnings ratio.
SNY is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.08, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.11 | ||
| Fwd PE | 9.83 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 96.35% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, SNY is valued cheaper than 89.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.21 | ||
| EV/EBITDA | 5.67 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SNY does not grow enough to justify the current Price/Earnings ratio.
SNY has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)3.62
PEG (5Y)2.18
EPS Next 2Y5.75%
EPS Next 3Y6.01%
5. Dividend
5.1 Amount
SNY has a Yearly Dividend Yield of 4.33%, which is a nice return.
Compared to an average industry Dividend Yield of 7.07, SNY pays a better dividend. On top of this SNY pays more dividend than 96.35% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.44, SNY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.33% |
5.2 History
The dividend of SNY has a limited annual growth rate of 4.30%.
SNY has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of SNY decreased in the last 3 years.
Dividend Growth(5Y)4.3%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
SNY pays out 34.82% of its income as dividend. This is a sustainable payout ratio.
The dividend of SNY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP34.82%
EPS Next 2Y5.75%
EPS Next 3Y6.01%
48.89
-0.66 (-1.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners47.5%
Inst Owner Change-5.61%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap119.09B
Revenue(TTM)66.91B
Net Income(TTM)13.81B
Analysts81.38
Price Target61.86 (26.53%)
Short Float %0.25%
Short Ratio1.79
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.33% |
Yearly Dividend2.21
Dividend Growth(5Y)4.3%
DP34.82%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.86%
Min EPS beat(2)-2.29%
Max EPS beat(2)6.02%
EPS beat(4)2
Avg EPS beat(4)4.01%
Min EPS beat(4)-2.29%
Max EPS beat(4)14.5%
EPS beat(8)4
Avg EPS beat(8)2.17%
EPS beat(12)7
Avg EPS beat(12)2.71%
EPS beat(16)11
Avg EPS beat(16)3.44%
Revenue beat(2)0
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-1.3%
Max Revenue beat(2)-0.63%
Revenue beat(4)1
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-4.57%
Max Revenue beat(4)3.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.12%
Revenue beat(12)4
Avg Revenue beat(12)9.26%
Revenue beat(16)8
Avg Revenue beat(16)21.08%
PT rev (1m)-2.99%
PT rev (3m)-3.27%
EPS NQ rev (1m)-0.89%
EPS NQ rev (3m)-7.4%
EPS NY rev (1m)-1.62%
EPS NY rev (3m)-5.41%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)-1.97%
Revenue NY rev (1m)0.96%
Revenue NY rev (3m)-0.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.11 | ||
| Fwd PE | 9.83 | ||
| P/S | 1.51 | ||
| P/FCF | 10.21 | ||
| P/OCF | 9.04 | ||
| P/B | 1.47 | ||
| P/tB | 11.06 | ||
| EV/EBITDA | 5.67 |
EPS(TTM)4.4
EY9%
EPS(NY)4.97
Fwd EY10.18%
FCF(TTM)4.79
FCFY9.79%
OCF(TTM)5.41
OCFY11.07%
SpS32.28
BVpS33.29
TBVpS4.42
PEG (NY)3.62
PEG (5Y)2.18
Graham Number57.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROCE | 16.7% | ||
| ROIC | 13.84% | ||
| ROICexc | 16.48% | ||
| ROICexgc | 66.95% | ||
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% | ||
| FCFM | 14.83% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
ROICexc(3y)8.13%
ROICexc(5y)7.97%
ROICexgc(3y)35.39%
ROICexgc(5y)35.54%
ROCE(3y)8.84%
ROCE(5y)8.55%
ROICexgc growth 3Y-13.63%
ROICexgc growth 5Y-1.43%
ROICexc growth 3Y-1.55%
ROICexc growth 5Y2.05%
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
F-Score7
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Debt/EBITDA | 0.75 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 58.05% | ||
| Profit Quality | 72.91% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 | ||
| Altman-Z | N/A |
F-Score7
WACC7.46%
ROIC/WACC1.86
Cap/Depr(3y)73.02%
Cap/Depr(5y)67.36%
Cap/Sales(3y)6.35%
Cap/Sales(5y)5.97%
Profit Quality(3y)113.82%
Profit Quality(5y)104.22%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
EPS Next Y3.07%
EPS Next 2Y5.75%
EPS Next 3Y6.01%
EPS Next 5Y7.06%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%
Revenue Next Year0.53%
Revenue Next 2Y3.48%
Revenue Next 3Y4.4%
Revenue Next 5Y4.52%
EBIT growth 1Y15.64%
EBIT growth 3Y1.33%
EBIT growth 5Y5.12%
EBIT Next Year30.73%
EBIT Next 3Y13.89%
EBIT Next 5Y11.66%
FCF growth 1Y24.23%
FCF growth 3Y-11.46%
FCF growth 5Y-0.14%
OCF growth 1Y10.87%
OCF growth 3Y-4.79%
OCF growth 5Y3.31%
SANOFI-ADR / SNY FAQ
What is the fundamental rating for SNY stock?
ChartMill assigns a fundamental rating of 6 / 10 to SNY.
What is the valuation status for SNY stock?
ChartMill assigns a valuation rating of 8 / 10 to SANOFI-ADR (SNY). This can be considered as Undervalued.
How profitable is SANOFI-ADR (SNY) stock?
SANOFI-ADR (SNY) has a profitability rating of 8 / 10.
What is the valuation of SANOFI-ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for SANOFI-ADR (SNY) is 11.11 and the Price/Book (PB) ratio is 1.47.
Can you provide the financial health for SNY stock?
The financial health rating of SANOFI-ADR (SNY) is 4 / 10.